34.40 USD
↘ 0.41 (1.19%)AT CLOSE (03:59 PM EDT)
Hemab Therapeutics Holdings, Inc. Common Stock
COAGNASDAQ • USD
34.27
↘ 0.14 (0.39%)
POST MARKET (AS OF 04:15 PM EDT)
Post Market
AS OF 04:15 PM EDT
34.27
↘ 0.14 (0.39%)
Market: CLOSED
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) trades at $34.40 per share. Technical indicators currently signal "Buy". Key drivers include a bullish Golden Cross on the moving averages.
Technical & fundamental data as of Oct 23, 2026.
Open?$34.58
High?$36.70
Low?$33.89
Prev. Close?$34.82
Volume?271.2K
Avg. Volume?N/A
VWAP?$34.44
Bid / Ask
Bid?$25.00 × 100
Ask?$42.87 × 100
Spread?$17.87
Midpoint?$33.94
Valuation & Ratios
Market Cap?1.6B
Shares Out?N/A
Float?6.3M
Float %?13.6%
P/E Ratio?N/A
P/B Ratio?N/A
EPS?N/A
Dividend?N/A
Ex-Dividend?N/A
News
Profile
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
Employees
N/A
Market Cap
1.6B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2026-05-01
Address
101 MAIN STREET
CAMBRIDGE, MA 02142
Phone: 45 2138 7627
CAMBRIDGE, MA 02142
Phone: 45 2138 7627
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental Outlook
Loading...
Short InterestSqueeze Risk
Short % of Float?53.57%Squeeze Risk
Short Interest?3.4M
Days to Cover?4.2
Free Float6.3M
Avg Daily Volume811.2K
Settlement Date2026-09-30